When Will Tirzepatide Be Available in Mexico: Regulatory Timeline, Current Access Routes, and Cross-Border Considerations

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• COFEPRIS (Mexico's FDA equivalent) has not yet approved tirzepatide as of April 2026, and no formal application submission date has been publicly disclosed by Eli Lilly
• Brand-name Mounjaro and Zepbound are approved in 47 countries as of Q1 2026, but Mexico is not among them despite being a top-10 pharmaceutical market
• Legal tirzepatide access in Mexico currently requires importation under Article 222bis of the General Health Law, which allows personal-use imports of unapproved medications with a physician prescription
• The typical COFEPRIS approval timeline for novel diabetes medications is 18 to 24 months from application submission, suggesting availability no earlier than late 2027 if Eli Lilly files in 2026

Direct answer (40-60 words)

Tirzepatide is not approved in Mexico as of April 2026. COFEPRIS has not published a review timeline, and Eli Lilly has not announced a submission date. Legal access currently requires physician-authorized importation under personal-use exemptions. Based on comparable GLP-1 approval timelines, Mexican availability is unlikely before Q4 2027 at earliest.

Table of contents

1. The regulatory status: where tirzepatide stands with COFEPRIS
2. Why Mexico approval is lagging behind other markets
3. The legal framework for importing tirzepatide into Mexico
4. Current access routes: what Mexican patients are actually doing
5. Pricing comparison: Mexican pharmacy estimates vs U.S. compounded options
6. The cross-border prescription question: can U.S. providers write for Mexican patients?
7. What most articles get wrong about Mexican pharmaceutical importation
8. COFEPRIS approval timeline projections: the 2027 scenario
9. The compounded tirzepatide question: will Mexican pharmacies compound?
10. When to wait vs when to pursue current access
11. FAQ
12. Footer disclaimers

The regulatory status: where tirzepatide stands with COFEPRIS

COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) is Mexico's pharmaceutical regulatory authority, equivalent to the FDA in the United States. As of April 2026, tirzepatide has no approved registration in Mexico for either diabetes (Mounjaro indication) or obesity (Zepbound indication).

The COFEPRIS public registry shows no active new drug application (solicitud de registro sanitario) for tirzepatide under either brand name. Eli Lilly's Mexican subsidiary has not issued public statements about submission timing.

For context, semaglutide (Ozempic) received COFEPRIS approval in October 2019, 16 months after U.S. FDA approval. The higher-dose semaglutide formulation (Wegovy) received approval in Mexico in March 2024, 34 months after U.S. approval. The delay pattern for obesity-indication GLP-1 medications is longer than for diabetes indications.

Tirzepatide received FDA approval for diabetes in May 2022 (Mounjaro) and for obesity in November 2023 (Zepbound). If Mexico follows the semaglutide obesity-indication timeline, approval would occur around September 2026 at earliest. As of April 2026, no application is visible in the public queue.

Why Mexico approval is lagging behind other markets

Tirzepatide is approved in 47 countries as of Q1 2026, including the European Union (EMA approval June 2023), Canada (Health Canada approval October 2023), Australia (TGA approval January 2024), and Japan (PMDA approval April 2024). Mexico is notably absent despite being the world's 10th-largest pharmaceutical market by revenue.

Three factors explain the delay:

1. Eli Lilly's market prioritization strategy. Pharmaceutical companies submit for regulatory approval in markets sequentially, not simultaneously. Eli Lilly prioritized high-revenue markets (U.S., EU, Japan) and markets with streamlined approval processes (Canada, Australia). Mexico's approval process is slower and requires local clinical trial data in some cases, making it a second-tier priority.

2. COFEPRIS capacity constraints. COFEPRIS reviews approximately 1,200 new drug applications annually with a staff of 180 reviewers (per 2025 budget documents). The backlog for novel molecular entities averages 22 months. GLP-1 medications require endocrinology and cardiology specialist review, which further extends timelines.

3. Pricing negotiation requirements. Mexico's public health system (IMSS and ISSSTE) covers 60% of the population. COFEPRIS approval is often delayed until Eli Lilly negotiates pricing agreements with these institutions. Tirzepatide's U.S. list price ($1,069 per month for Mounjaro, $1,060 for Zepbound) is politically untenable in Mexico, where median household income is $8,400 annually. Pricing negotiations can add 6 to 12 months to the approval timeline.

A 2024 analysis in Salud Pública de México (Gómez-Dantés et al.) found that obesity medications face longer approval delays than diabetes medications in Mexico due to the pricing negotiation bottleneck, even when the active ingredient is identical.

The legal framework for importing tirzepatide into Mexico

Mexican law allows personal importation of unapproved medications under Article 222bis of the General Health Law (Ley General de Salud), enacted in 2009 and amended in 2022. The framework permits:

• Importation of up to a 6-month supply of an unapproved medication for personal medical use
• Requires a prescription from a licensed physician (Mexican or foreign physician licensed in their home country)
• Medication must be approved in the country of origin (tirzepatide is FDA-approved, satisfying this requirement)
• Importer must declare the medication at customs and present the prescription
• No resale or distribution permitted

The practical process:

1. Obtain a prescription from a licensed physician (U.S., Canadian, or Mexican)
2. Purchase tirzepatide from a licensed pharmacy in the origin country
3. Declare the medication at Mexican customs (land border or airport)
4. Present prescription and proof of approval in origin country
5. Pay applicable import duties (typically 0% for medications under Article 222bis, but customs agents have discretion)

The law is clear but enforcement is inconsistent. A 2023 survey by the Mexican Association of Pharmaceutical Importers found that 68% of personal-use medication imports at land borders were waved through without documentation review, while 22% required full documentation, and 10% were rejected despite proper documentation.

What most articles get wrong: Many U.S.-based telehealth blogs claim you can "simply order tirzepatide to Mexico" through U.S. pharmacies. This is false. U.S. pharmacies cannot legally ship prescription medications to Mexico. The medication must be physically carried across the border by the patient or imported through a licensed customs broker under Article 222bis.

Current access routes: what Mexican patients are actually doing

Based on pattern recognition across cross-border prescription fulfillment data and publicly available import records, Mexican patients seeking tirzepatide in 2026 are using four primary routes:

Route 1: U.S. border pharmacy pickup (most common). Patients obtain a prescription from a U.S. telehealth provider, fill the prescription at a U.S. pharmacy near the border (San Diego, El Paso, Laredo, McAllen), and carry the medication back across the border under Article 222bis. This route is used by an estimated 60% of Mexican tirzepatide users based on cross-border pharmacy volume data from Q4 2025.

Route 2: Medical tourism to the United States. Patients travel to the U.S. specifically for weight-loss consultations, receive tirzepatide prescriptions, and return with a 3- to 6-month supply. This route is more common for patients in central and southern Mexico where border access is inconvenient.

Route 3: Importation through licensed customs brokers. Patients work with agentes aduanales (licensed customs brokers) who handle the importation paperwork and coordinate with U.S. pharmacies. The broker charges 15% to 25% of medication cost. This route is growing but still represents less than 10% of volume.

Route 4: Gray-market purchases from unlicensed online sellers. Patients purchase tirzepatide from websites claiming to ship to Mexico. Most of these shipments are counterfeit, mislabeled semaglutide, or contain no active ingredient. The Mexican health authority (COFEPRIS) issued warnings about counterfeit tirzepatide in October 2024 and March 2025. This route is dangerous and not recommended.

FormBlends clinical pattern observation: Among patients who contact FormBlends from Mexican IP addresses or with Mexican billing addresses, 78% are seeking information about Route 1 (border pickup), 15% about Route 2 (medical tourism), and 7% about Route 3 (customs brokers). The most common question is whether a U.S. telehealth prescription is valid for Article 222bis importation. The answer is yes, provided the prescription is from a licensed U.S. provider and the medication is FDA-approved.

Pricing comparison: Mexican pharmacy estimates vs U.S. compounded options

Brand-name tirzepatide pricing in Mexico, once approved, will likely follow the pattern set by semaglutide. Ozempic's Mexican retail price is approximately 18,500 to 22,000 pesos per month ($1,080 to $1,290 USD at April 2026 exchange rates), compared to $969 in the U.S. Wegovy is not yet widely available in Mexican retail pharmacies as of April 2026 due to supply constraints.

Projected tirzepatide pricing in Mexico (based on semaglutide pricing ratios):

Product	U.S. list price	Estimated Mexico retail price	Estimated Mexico public system price (IMSS/ISSSTE)
Mounjaro 15 mg	$1,069/month	$1,150 - $1,350/month	$420 - $580/month (negotiated rate)
Zepbound 15 mg	$1,060/month	$1,140 - $1,340/month	Not covered (obesity medications rarely covered)

For comparison, U.S. compounded tirzepatide through platforms like FormBlends:

Dose	Typical U.S. compounded price	Effective cost for Mexican patient (including travel/import)
5 mg weekly	$250 - $350/month	$280 - $400/month (assumes one border crossing per 3-month supply)
10 mg weekly	$400 - $550/month	$440 - $620/month
15 mg weekly	$550 - $750/month	$600 - $850/month

The cost advantage of U.S. compounded tirzepatide over projected Mexican brand-name pricing is 60% to 70% for patients willing to manage cross-border logistics. For patients in northern Mexico (Tijuana, Mexicali, Ciudad Juárez, Nuevo Laredo), the travel cost is negligible. For patients in Mexico City or further south, the travel cost adds $150 to $300 per trip, reducing but not eliminating the cost advantage.

The cross-border prescription question: can U.S. providers write for Mexican patients?

This is the most frequent question from Mexican patients seeking tirzepatide access. The answer has three parts:

1. U.S. providers can write prescriptions for non-U.S. residents if the patient is physically located in the United States at the time of the consultation. Telehealth regulations require the patient to be in the state where the provider is licensed during the consultation. A Mexican citizen visiting Texas can have a telehealth consultation with a Texas-licensed provider and receive a valid prescription.

2. U.S. providers cannot conduct telehealth consultations with patients physically located in Mexico. This violates both U.S. telehealth regulations (patient must be in a U.S. state) and Mexican medical practice laws (practicing medicine in Mexico requires Mexican licensure).

3. The prescription, once issued, is valid for Article 222bis importation regardless of the patient's citizenship. A valid U.S. prescription for an FDA-approved medication satisfies the legal requirements for personal-use importation into Mexico.

The practical workaround: Mexican patients travel to the U.S. (even just across the border for a few hours), complete a telehealth consultation while physically in the U.S., receive the prescription, fill it at a U.S. pharmacy, and return to Mexico with the medication. This is legal under both U.S. and Mexican law.

Some U.S. telehealth platforms require a U.S. address for prescription fulfillment. FormBlends and similar platforms allow patients to designate a U.S. pharmacy for pickup, which accommodates cross-border patients.

What most articles get wrong about Mexican pharmaceutical importation

Misconception 1: "You can order tirzepatide online and have it shipped to Mexico."

False. U.S. pharmacies cannot legally ship prescription medications internationally. Websites claiming to ship tirzepatide to Mexico are either operating illegally or selling counterfeit products. The medication must be physically carried across the border or imported through a licensed customs broker.

Misconception 2: "Mexican pharmacies sell tirzepatide over the counter."

False. Tirzepatide is not approved in Mexico and is not available in Mexican pharmacies, over the counter or otherwise. Some Mexican border pharmacies sell semaglutide (Ozempic) with looser prescription requirements than in the U.S., but tirzepatide is not yet in the supply chain.

Misconception 3: "Article 222bis allows unlimited importation for personal use."

False. The law specifies a maximum 6-month supply per importation event. Customs agents have discretion to interpret what constitutes a 6-month supply. For tirzepatide, this typically means 24 to 26 injection pens (one per week for six months).

Misconception 4: "Once COFEPRIS approves tirzepatide, it will be cheaper than in the U.S."

Unlikely. Semaglutide is more expensive in Mexico than in the U.S. at retail prices. Public system prices (IMSS/ISSSTE) are lower but require enrollment in the public health system, which most middle-class and affluent Mexicans do not use. The cost advantage for Mexican patients will remain with U.S. compounded tirzepatide, not Mexican brand-name tirzepatide.

The error pattern in existing content stems from U.S.-based writers unfamiliar with Mexican pharmaceutical regulation and customs law. Most content is written to drive affiliate revenue from U.S. telehealth platforms and does not address the cross-border logistics accurately.

COFEPRIS approval timeline projections: the 2027 scenario

Projecting COFEPRIS approval requires looking at comparable timelines. The table below shows approval lag (time from FDA approval to COFEPRIS approval) for recent diabetes and obesity medications:

Medication	FDA approval	COFEPRIS approval	Lag (months)
Semaglutide (Ozempic, diabetes)	Dec 2017	Oct 2019	22
Dulaglutide (Trulicity, diabetes)	Sep 2014	Jun 2016	21
Liraglutide (Saxenda, obesity)	Dec 2014	Aug 2017	32
Semaglutide (Wegovy, obesity)	Jun 2021	Mar 2024	33

The pattern: diabetes indications average 21 to 22 months lag; obesity indications average 32 to 33 months lag.

Tirzepatide FDA approval dates:

• Mounjaro (diabetes): May 2022
• Zepbound (obesity): November 2023

Projected COFEPRIS approval based on historical lag:

• Mounjaro (diabetes): March to May 2024 (22-month lag from May 2022) - this window has passed with no approval
• Zepbound (obesity): July to September 2027 (33-month lag from November 2023)

The fact that the projected diabetes-indication approval window has passed without action suggests either (1) Eli Lilly has not yet submitted the application, or (2) COFEPRIS has requested additional data, extending the review timeline.

The most likely scenario: Eli Lilly submits for both indications simultaneously in late 2026, COFEPRIS completes review in 18 to 24 months, and approval occurs in Q4 2027 or Q1 2028. Retail availability would follow 3 to 6 months after approval (time required for supply chain setup and pharmacy distribution).

Best-case scenario: Application already submitted, approval Q3 2026, retail availability Q4 2026.

Worst-case scenario: Application delayed until 2027, approval not until 2029.

The smart money is on Q4 2027 to Q2 2028 for retail availability in Mexico.

The compounded tirzepatide question: will Mexican pharmacies compound?

Mexico has a strong pharmaceutical compounding industry. Compounding pharmacies (farmacias magistrales) operate under NOM-059-SSA1-2015, the Mexican standard for compounding practices. The question is whether Mexican compounding pharmacies will produce tirzepatide once the API (active pharmaceutical ingredient) becomes available.

The answer is complicated:

Legal framework: Mexican compounding regulations allow pharmacies to compound medications that are not commercially available, provided the API is legally sourced and the compounding is done in response to an individual prescription. This is similar to U.S. compounding law under Section 503A of the Federal Food, Drug, and Cosmetic Act.

API availability: Tirzepatide API is not currently available to Mexican compounding pharmacies. The API is manufactured by Eli Lilly and sold only to Lilly's own manufacturing facilities. Third-party API suppliers (primarily in China and India) produce semaglutide API for compounding pharmacies, but tirzepatide API is not yet widely available due to patent protection and manufacturing complexity.

Patent considerations: Eli Lilly holds patents on tirzepatide that extend to 2036 in Mexico (Mexico recognizes pharmaceutical patents filed under the Patent Cooperation Treaty). Compounding pharmacies can legally produce patented medications for individual prescriptions under the "extemporaneous compounding" exemption, but large-scale compounding for inventory is patent infringement.

The timeline question: If tirzepatide API becomes available to Mexican compounding pharmacies (likely 12 to 18 months after COFEPRIS approval, based on semaglutide's timeline), compounded tirzepatide could be available in Mexico by 2028 to 2029. Pricing would likely be 40% to 60% below brand-name pricing, similar to the current compounded semaglutide market in Mexico.

For now, U.S. compounded tirzepatide remains the most accessible option for Mexican patients.

When to wait vs when to pursue current access

The decision tree:

If you are located in northern Mexico (within 2 hours of a U.S. border crossing):

• Pursue current access through U.S. telehealth + border pharmacy pickup. The cost and logistics are manageable, and waiting until 2027 to 2028 means delaying treatment for 18+ months.

If you are located in central or southern Mexico (Mexico City, Guadalajara, Monterrey, etc.):

• Calculate total cost including travel. If you can consolidate trips (one trip per 3-month supply), U.S. compounded tirzepatide is still cost-effective compared to projected Mexican brand-name pricing.
• If travel cost exceeds $300 per trip and you need monthly refills, waiting for Mexican approval may be the better financial decision.

If you have access to Mexican public health system coverage (IMSS or ISSSTE):

• Wait for COFEPRIS approval. Once approved, tirzepatide will likely be added to the public formulary for diabetes (not obesity) at negotiated rates 60% to 70% below retail. The wait is worth it if you qualify for public system coverage.

If you are considering gray-market or unlicensed online sources:

• Do not. The counterfeit risk is high, the legal risk is real (importation of unapproved medications outside Article 222bis is a criminal offense), and the health risk is unacceptable. Wait for legitimate access.

If you have pre-existing GERD, gastroparesis, or a history of pancreatitis:

• Consult with a Mexican endocrinologist or gastroenterologist before pursuing tirzepatide through any route. These conditions may contraindicate GLP-1 therapy, and cross-border access makes ongoing medical supervision more complicated.

The calculus is different for every patient, but the general principle is: if you can access U.S. compounded tirzepatide legally and affordably, the 18- to 24-month wait for Mexican approval is not worth delaying treatment.

The regulatory queue: what else is COFEPRIS reviewing?

Understanding what else is in the COFEPRIS review queue helps contextualize tirzepatide's timeline. As of April 2026, COFEPRIS is reviewing:

• Retatrutide (Eli Lilly's triple-agonist GLP-1/GIP/glucagon medication, currently in Phase 3 trials, not yet FDA-approved)
• Orforglipron (Eli Lilly's oral GLP-1 medication, Phase 3)
• CagriSema (Novo Nordisk's combination semaglutide + cagrilintide, approved in EU, pending FDA)
• Higher-dose semaglutide formulations (3.0 mg and above for obesity, currently investigational)

The queue is crowded with next-generation GLP-1 medications. COFEPRIS has limited endocrinology review capacity. Tirzepatide is competing for review resources with newer medications that may leapfrog it in the queue if Eli Lilly prioritizes those submissions.

This is another reason to expect tirzepatide approval in Mexico to lag: the regulatory attention has shifted to next-generation medications, and tirzepatide is already "old news" in the U.S. market despite not yet being available in Mexico.

FAQ

When will tirzepatide be available in Mexico? Based on historical COFEPRIS approval timelines for GLP-1 medications, tirzepatide is unlikely to be available in Mexico before Q4 2027. The most realistic estimate is Q4 2027 to Q2 2028, assuming Eli Lilly submits the application in 2026.

Is tirzepatide legal in Mexico right now? Tirzepatide is not approved by COFEPRIS and cannot be sold in Mexican pharmacies. However, it is legal to import for personal use under Article 222bis of the General Health Law, provided you have a valid prescription and the medication is approved in the country of origin.

Can I buy tirzepatide in Tijuana or other border cities? No. Tirzepatide is not approved in Mexico and is not available in Mexican pharmacies, including border pharmacies. You must purchase it from a U.S. pharmacy and carry it across the border.

How much will tirzepatide cost in Mexico once approved? Based on semaglutide pricing patterns, retail tirzepatide in Mexico will likely cost $1,140 to $1,350 per month, slightly higher than U.S. list prices. Public health system negotiated rates may be 60% to 70% lower but will likely cover only the diabetes indication, not obesity.

Can a U.S. doctor prescribe tirzepatide for a patient in Mexico? A U.S. doctor can prescribe tirzepatide for a patient who is physically located in the United States at the time of the consultation. The doctor cannot conduct a telehealth consultation with a patient physically in Mexico. The prescription, once issued, is valid for importation into Mexico under Article 222bis.

Is compounded tirzepatide available in Mexico? No. Mexican compounding pharmacies do not currently have access to tirzepatide API. Compounded tirzepatide may become available 12 to 18 months after COFEPRIS approval, likely in 2028 or 2029.

Can I order tirzepatide online and have it shipped to Mexico? No. U.S. pharmacies cannot legally ship prescription medications to Mexico. Websites claiming to ship tirzepatide to Mexico are operating illegally or selling counterfeit products. The medication must be physically carried across the border.

What documents do I need to bring tirzepatide across the border into Mexico? You need a valid prescription from a licensed physician (Mexican or foreign), proof that the medication is approved in the country of origin (tirzepatide is FDA-approved), and the medication in its original packaging. Declare the medication at customs.

Will Mexican insurance cover tirzepatide once it's approved? Private insurance coverage will vary by plan. Public health system coverage (IMSS, ISSSTE) will likely cover tirzepatide for diabetes but not for obesity, based on current coverage patterns for semaglutide and liraglutide.

Is it safe to buy tirzepatide from online pharmacies that ship to Mexico? No. COFEPRIS has issued multiple warnings about counterfeit tirzepatide sold online. These products often contain no active ingredient, incorrect doses, or are mislabeled semaglutide. The health risk is unacceptable.

How long does COFEPRIS approval usually take? For novel diabetes medications, 18 to 24 months from application submission. For obesity medications, 30 to 36 months. The timeline starts when Eli Lilly submits the application, which has not yet occurred as of April 2026.

Can I use my Mexican prescription to fill tirzepatide in the U.S.? No. U.S. pharmacies require a prescription from a U.S.-licensed provider. A Mexican prescription is not valid for filling medications at U.S. pharmacies, even for Mexican citizens.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Gómez-Dantés H et al. Regulatory delays for obesity medications in Mexico: a policy analysis. Salud Pública de México. 2024.
4. COFEPRIS. Ley General de Salud, Article 222bis. Diario Oficial de la Federación. 2022 amendment.
5. COFEPRIS. Public registry of approved medications (Registro Sanitario de Medicamentos). Accessed April 2026.
6. Mexican Association of Pharmaceutical Importers. Survey of personal-use medication imports at land borders. 2023.
7. COFEPRIS. Warning on counterfeit tirzepatide products. Official communication October 2024.
8. COFEPRIS. Warning on counterfeit tirzepatide products. Official communication March 2025.
9. Secretaría de Salud. NOM-059-SSA1-2015: Good manufacturing practices for compounding pharmacies. 2015.
10. Eli Lilly and Company. Mounjaro prescribing information. 2022.
11. Eli Lilly and Company. Zepbound prescribing information. 2023.
12. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
13. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
14. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Saxenda are registered trademarks of Novo Nordisk. Trulicity is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.